ILMNIllumina, Inc.

1. Aug 17, 2026On August 17, 2026, Illumina, Inc. (“Illumina” or the “Company”) completed a public offering of $300,000,000 aggregate principal amount of its 4.950% notes due 2029 (the “Notes”)Other event · Form 8-K
2. Aug 13, 2026Entry into Credit Agreement On August 13, 2026, Illumina, Inc. (“Illumina” or the “Company”) entered into a credit agreement (the “Credit Agreement”) among the Company, as the borrower, the lenders from time to time party thereto, Bank of America, N.A., as administrative agent, an issuing bank and the swingline …Material agreement entered · Form 8-K
3. Aug 12, 2026On August 10, 2026, Illumina, Inc. (“Illumina”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein, for the issuance and sale by Illumina of $300,000,000 aggregate …Other event · Form 8-K
4. Aug 7, 2026Effective August 21, 2025, Illumina, Inc. (the “Company”) entered into a Release Agreement with the plaintiffs and all named defendants reflecting the terms of the settlement of the litigation captioned Icahn Partners LP, et al., v.Other event · Form 8-K
5. Jun 23, 2026On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately.Director or officer change · Form 8-K
6. Apr 30, 2026On April 28, 2026, the Company’s Board of Directors authorized a new share repurchase program for up to $1.5 billion of the Company’s common stock (the “2026 Repurchase Program”)Earnings release · Form 8-K
7. Apr 2, 2026On April 2, 2026, each of Drs. Frances Arnold, Robert S. Epstein and Gary S. Guthart notified the Board of Directors (the "Board") of Illumina, Inc. (the "Company") of her or his intention to retire as a director of the Company, effective as of May 21, 2026 (the date of the Company’s 2026 annual meeting of stockholders)Director or officer change · Form 8-K
8. Jan 30, 2026As previously disclosed in the Current Report on Form 8-K filed by Illumina, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on June 23, 2025, the Company entered into a Stock Purchase Agreement, dated as of June 22, 2025 (the “Purchase Agreement”), with Standard BioTools Inc. (“Standard …Acquisition or disposition completed · Form 8-K
9. Jan 13, 2026Illumina Announces Preliminary Unaudited Financial Results.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.